Lexaria Bioscience Corp.
LEXX
$4.52
-$1.35-22.93%
NASDAQ
| 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -68.50% | -30.02% | 5.05% | 52.04% | 49.85% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -68.50% | -30.02% | 5.05% | 52.04% | 49.85% |
| Cost of Revenue | -100.00% | -100.00% | -100.00% | -43.75% | -43.75% |
| Gross Profit | -68.36% | -29.66% | 5.63% | 53.04% | 50.96% |
| SG&A Expenses | -21.26% | -18.16% | 1.36% | 7.25% | 52.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -35.99% | -2.97% | 41.92% | 99.00% | 141.75% |
| Operating Income | 34.23% | 1.46% | -44.42% | -102.79% | -150.04% |
| Income Before Tax | 32.15% | -1.48% | -47.34% | -105.06% | -134.05% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 32.11% | -1.53% | -47.37% | -105.06% | -134.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -15.00% | -26.13% | -12.38% | -27.82% | -52.83% |
| Net Income | 32.12% | -1.56% | -47.45% | -105.37% | -134.87% |
| EBIT | 34.23% | 1.46% | -44.42% | -102.79% | -150.04% |
| EBITDA | 34.43% | 1.70% | -45.05% | -103.97% | -155.55% |
| EPS Basic | 46.95% | 18.14% | -17.16% | -44.43% | -40.50% |
| Normalized Basic EPS | 48.83% | 20.48% | -15.06% | -44.00% | -53.18% |
| EPS Diluted | 46.95% | 18.14% | -17.16% | -44.43% | -40.50% |
| Normalized Diluted EPS | 48.83% | 20.48% | -15.06% | -44.00% | -53.18% |
| Average Basic Shares Outstanding | 32.28% | 31.29% | 34.67% | 45.91% | 63.21% |
| Average Diluted Shares Outstanding | 32.28% | 31.29% | 34.67% | 45.91% | 63.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |